An Open-Label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of PUL-042 Inhalation Solution in Subjects With Hematologic Malignancies and Recipients of Stem Cell Transplantation
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 10 Apr 2018
At a glance
- Drugs ODN/Pam2 (Primary)
- Indications Pneumocystis pneumonia
- Focus Therapeutic Use
- Sponsors Pulmotect
- 03 Apr 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.
- 03 Apr 2018 Planned primary completion date changed from 1 Sep 2018 to 1 Sep 2019.
- 03 Apr 2018 Planned initiation date changed from 1 Sep 2017 to 1 May 2018.